Drug Trial Radar · NCT05539651
A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044
Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Nov 10, 2022
Primary completion
Oct 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I study to evaluate the safety, tolerability, PK profiles and PD effect of single and multiple ascending doses of subcutaneously administered RBD5044 in healthy subjects. The study will be performed in 2 phases: single ascending dose (SAD) phase and multiple ascending doses (MAD) phase in healthy subjects. There are 6 cohorts in SAD phases, the dose levels are 5mg, 20mg, 60mg, 90mg, 120mg and 150mg. There are 3 cohorts in MAD phases, the dose levels are 60mg, 90mg and 120mg.The decision to escalate to subsequent dose levels will be made by the SRC based on the review of all available safety information, including AEs, ECGs, vital signs, and clinical laboratory test results in each cohort.
Conditions
- Health Volunteer
Interventions
RBD5044Drug
Subcutaneously Administered RBD5044 in Healthy Subjects
PlaceboDrug
Subcutaneously Administered Placebo in Healthy Subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v5.0Time frame: SAD: Up to 24 weeks; MAD: Up to 28 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Limited
Brisbane, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.